Accenture Invests in Earli Inc. to Advance Technologies for Early Cancer Detection
19 August 2024 - 1:59PM
Business Wire
Accenture (NYSE: ACN) has made a strategic investment, through
Accenture Ventures, in Earli Inc., a biotechnology company that
developed a novel approach to early cancer detection with a
synthetic targeting platform that selectively reprograms cancer
cells to reveal and destroy themselves. This investment from
Accenture Ventures will support expanding collaborations with
global health and pharma companies that can use Earli’s technology
to more rapidly and accurately detect and treat cancer.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240819448521/en/
Accenture has made a strategic
investment, through Accenture Ventures, in Earli Inc., a
biotechnology company that developed a novel approach to early
cancer detection with a synthetic targeting platform that
selectively reprograms cancer cells to reveal and destroy
themselves. (Graphic: Business Wire)
Based in Redwood City, California, Earli’s mission is to
transform cancer into a benign experience by solving one of the
most difficult challenges in oncology: reliably distinguishing
between healthy and cancerous cells. Earli’s approach uses
programmable genetic constructs that react and signal the presence
of active cancer cells at an early stage. The synthetic biopsy
approach enhances the sensitivity and specificity of cancer
detection for an earlier diagnosis, allowing pharmaceutical and
biotech companies to create personalized treatments more quickly
and often at a lower cost.
Petra Jantzer, Ph.D., a senior managing director and global lead
of the Accenture Life Sciences business, said, “Earli’s synthetic
biopsy method is a step change in early cancer detection
technologies and will offer significant advantages to biopharma
companies by improving the precision and efficacy of new treatments
and diagnostics, as well as in understanding the mechanisms of
cancer progressions.”
Early detection and treatment are proving critical in
dramatically increasing chances for successful treatment of cancer
and remission. Earli’s technology has the potential to discover the
presence and location of multiple types of cancer through
non-invasive screening techniques including blood samples and PET
(positron emission tomography) scans, even tumors that are too
small to be detected through existing methods.
“Accenture’s impressive network of biopharma clients will be
very impactful for Earli. It is fantastic to have Accenture support
our mission to make cancer a benign experience," said Cyriac
Roeding, Co-Founder & CEO, Earli Inc.
“Earli’s technology is built on decades of biological data that
analyzes multiple factors and identifies specific proteins that
cause cancer development, increasing the effectiveness and
reliability of the synthetic biopsy process,” said Tom Lounibos,
global lead for Accenture Ventures. “With Earli joining our Project
Spotlight program, we can collaborate with our clients in the
biopharma industry to advance their capabilities in cancer
research, drug development and patient care.”
Earli is the latest company to join Accenture Ventures’ Project
Spotlight, an engagement and investment program working with
companies that create or apply disruptive enterprise technologies.
Project Spotlight offers extensive access to Accenture’s domain
expertise and its enterprise clients, helping startups harness
creativity and deliver on the promise of their technology.
Additional biotechnology companies that have joined Project
Spotlight include Turbine, QuantHealth, Virtonomy and Ocean
Genomics.
Terms of the investment were not disclosed.
About Accenture
Accenture is a leading global professional services company that
helps the world’s leading businesses, governments and other
organizations build their digital core, optimize their operations,
accelerate revenue growth and enhance citizen services—creating
tangible value at speed and scale. We are a talent- and
innovation-led company with approximately 750,000 people serving
clients in more than 120 countries. Technology is at the core of
change today, and we are one of the world’s leaders in helping
drive that change, with strong ecosystem relationships. We combine
our strength in technology and leadership in cloud, data and AI
with unmatched industry experience, functional expertise and global
delivery capability. We are uniquely able to deliver tangible
outcomes because of our broad range of services, solutions and
assets across Strategy & Consulting, Technology, Operations,
Industry X and Song. These capabilities, together with our culture
of shared success and commitment to creating 360° value, enable us
to help our clients reinvent and build trusted, lasting
relationships. We measure our success by the 360° value we create
for our clients, each other, our shareholders, partners and
communities. Visit us at www.accenture.com.
About Earli
Earli Inc. is a biotechnology company focused on making cancer
that is detected early, localizable and therefore treatable, via
its novel “Synthetic Biopsies.” By forcing cancer cells to produce
synthetic biomarkers that do not belong in the human body, they are
made highly detectable and localizable in a PET scanner, so they
can be treated at early stages, when survival rates are multiple
times higher. Earli uses biology rather than chemistry to force
production of the Synthetic Biopsy, allowing for massive signal
amplification and targeted treatment. The company is located in
South San Francisco’s biotech hub.
Copyright ©2024 Accenture. All rights reserved. Accenture and
its logo are registered trademarks of Accenture.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240819448521/en/
Marchell Gillis Accenture +1 678 657 7515
marchell.gillis@accenture.com
Keerthi Goutham Accenture +91 99000 94099
Keerthi.goutham@accenture.com
Accenture (NYSE:ACN)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Accenture (NYSE:ACN)
Historical Stock Chart
Von Okt 2023 bis Okt 2024